Traditional and novel risk factors of premature coronary heart disease and correlation between Triglyceride-glucose index and multivessel disease

Ao Wei

Tianjin Chest Hospital

Jingjing Liu

Tianjin Chest Hospital

Le Wang

Tianjin Chest Hospital

Senshuang Zheng

University of Groningen, University Medical Centre Groningen

Hongliang Cong (✉ hongliangcong@126.com)

Tianjin Chest Hospital

Research Article

Keywords: Coronary heart disease, Risk factors, Insulin resistance, Vascular disease, Prevention

Posted Date: March 1st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1396508/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: For a decade, the incidence and global burden of coronary heart disease (CHD) has increased in the young population. To identify the characteristics of premature CHD patients and to determine the risk factors of premature CHD and multivessel disease (MVD).

Methods: A total of 2846 patients were enrolled in this retrospective, cross-sectional study. Premature CHD is defined as men <45 years and women <55 years. Demographic and clinical data were collected from the database of patient medical records. Logistic regression models were applied to analyse the characteristics and risk factors of premature CHD and MVD.

Results: Most characteristics between premature and mature CHD patients were not statistically significant. A significantly higher rate of dyslipidaemia was found in female premature CHD patients (OR=1.412, 95%CI:1.029-1.936). In the crude models, female patients with the highest TyG index level were more likely to have premature MVD (OR=2.065, 95%CI:1.426-2.991) or mature MVD (OR=1.837, 95%CI:1.104-3.056) than those with the lowest TyG index group instead of premature single-vessel disease. Among male patients, the same trend was observed in mature MVD of CHD (OR=2.272, 95%CI:1.312-3.937). The significance of the TyG index was not revealed in the multivariate analyses; however, hypertension, diabetes, obesity, smoking, OMI, and Lp(a) showed a positive association with MVD.

Conclusions: Dyslipidaemia should be used as an effective factor for the prediction and prevention of premature CHD in women. The TyG index could be a simple auxiliary indicator to be applied in population-based cardiovascular disease screening for initial identification of vascular disease severity.

Background

Cardiovascular diseases (CVDs) are the leading cause of death worldwide [1]. Coronary heart disease (CHD), an atherosclerotic disease which is the principal burden of CVDs, caused 9.14 million deaths, accounting for 16.2% of all deaths globally [2]. In China, it was estimated that over 11 million patients are currently suffering with CHD [3]. Although more than half of new cases are in people aged over 70, researchers observed that the incidence has risen in younger people [4–6]. The latest data showed that 17.9% of new cases were in people under 55 years old, and 12.3% of deaths were in people under 60 years nationally [7].

Across several guidelines and studies, premature CHD has been defined as males < 55 or < 45 years and females < 65 or < 55 years [8, 9]. Compared with mature CHD, patients with premature CHD usually have more acute coronary syndrome (ACS), worse prognosis, and a higher burden of disease [10, 11]. Prior studies have noted several risk factors for atherosclerosis and CHD, including male gender, obesity, diabetes, smoking, dyslipidaemia, hypertension, and insulin resistance (IR) [4, 12–14]. In addition, Singh et al., Panwar et al., and Zhou et al. revealed the correlation between premature CHD and familial hypercholesterolemia, apolipoprotein B, and homocysteine respectively [6, 15, 16]. As a novel marker of IR, triglyceride-glucose (TyG) index has been widely used in recent cardiovascular studies [17–21]. It has been observed that an increased TyG index is associated with a higher risk of CVD, artery calcification, and major

adverse cardiovascular events [18, 21]. Furthermore, Wang et al. reported the relevancy of multivessel disease (MVD) of CHD and high TyG index, and worse outcomes were found in the MVD than in the single-vessel disease (SVD) [21–23].

Few studies have investigated the differences between the patient characteristics with premature and mature CHD, as well as the correlation of TyG index and traditional risk factors with premature CHD and the vascular disease severity. This study therefore aims to identify the characteristics of premature CHD patients and to determine the risk factors of premature CHD and MVD. This may help to improve the prevention and diagnosis of premature CHD and to reduce the burden of disease.

Methods

Study design and population

We applied a single-centre, retrospective, cross-sectional study. The patients enrolled in the study were females < 60 and males < 50 years old who had received a first diagnosis of CHD in Tianjin Chest Hospital between 2014 and 2017. An instance of CHD was defined as (a) coronary angiography showing any coronary artery stenosis $\geq 50\%$ of the diameter, or (b) patient had typical symptoms, changes in cardiac biomarker level and electrocardiographic evidence [24]. The classification of CHD was according to the 10th Revision of the International Classification of Diseases (ICD-10). Four types of CHD were considered in this study, namely stable angina (SA, ICD-10-CM code I20.8), unstable angina (UA, ICD-10-CM code I20.0), non-ST-segment elevation myocardial infarction (NSTEMI, ICD-10-CM code I21.4), and ST-segment elevation myocardial infarction (STEMI, ICD-10-CM code I21.0, I21.1, I21.2, I21.3). Patients with a history of CHD, or history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) were excluded, as were those without independent behavioural and cognitive abilities. A total of 2846 patients were included in the analysis. The age for premature CHD was determined as < 45 years for male patients and < 55 years for female patients [8]. This study adhered to the Declaration of Helsinki and was approved by the Medical Ethics Committee of Tianjin Chest Hospital (No. 2018XKZ23). All patients enrolled in this study provided verbal informed consent.

Data collection

Demographic and clinical data were obtained from the database of patient medical records maintained in the Tianjin Chest Hospital by trained clinicians. We extracted the baseline data of the patient's first diagnosis. The data collection consisted of information on sociodemographic characteristics (age, gender), behaviour (smoking), disease history (hypertension, diabetes), family history of CHD, clinical and serum biochemical indicators (body mass index (BMI), left ventricle ejection fraction (LVEF), haemoglobin (Hb), fasting blood glucose (FBG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), lipoprotein (a) (Lp(a)), C-reactive protein (CRP), creatinine (Cre)), and the disease characteristics ((SVD or MVD), old myocardial infarction (OMI), types of CHD).

Definitions

Hypertension and diabetes were determined by the attending physician combining the patient's self-report, clinical presentation, and results of resting blood pressure measurements or oral glucose tolerance test (OGTT). BMI was calculated applying weight (kg)/height (m²). BMI ≥ 24.0 is overweight and obesity, and BMI < 24.0 is underweight and normal [25]. The diagnosis of dyslipidaemia was based on the 2016 Chinese guideline for the management of dyslipidaemia in adults. Hypercholesterolaemia with TC ≥ 5.2 mmol/L, hyperglyceridaemia with TG ≥ 1.7 mmol/L, mixed hyperlipidaemia with TC ≥ 5.2 mmol/L and TG ≥ 1.7 mmol/L, and HDL-C deficiency with HDL-C < 1.0 mmol/L were defined as dyslipidaemia [26]. MVD was defined as at least 2 vessels with $\geq 50\%$ stenosis [27]. TyG index was calculated using $\ln[(\text{fasting triglyceride (mg/dL)} \times \text{fasting blood glucose (mg/dL)})/2]$ [28]. The patients were divided into quartiles by TyG index: quartile 1 (TyG index ≤ 8.5711), quartile 2 ($8.5711 < \text{TyG index} \leq 8.9731$), quartile 3 ($8.9731 < \text{TyG index} \leq 9.3975$), and quartile 4 (TyG index > 9.3975). BMI, smoking, hypertension, diabetes, dyslipidaemia, and family history were considered as traditional risk factors for CHD.

Statistical analysis

The age for premature CHD was different between male and female patients, and the analysis also showed that the differences on several variables between the genders were statistically significant (Additional file 1, Table A1). Thus, all data analyses were stratified by gender. Descriptive statistics was used, including mean $\pm$ standard deviation for continuous variables, median and inter-quartile range (IQR) for non-normally distributed continuous variables, and frequencies for categorical variables. Sociodemographic and clinical characteristics were compared between premature and mature CHD groups by the t-test, analysis of variance or Mann-Whitney U test for continuous variables, and Chi-square test for categorical variables. Binary logistic regression analyses were applied to reveal the characteristics and determinants of premature CHD compared with mature CHD; multinomial logistic regression analyses were applied to identify the correlation between the risk factors and the onset age of MVD and SVD in CHD. The crude models (model 1) used quartile of TyG Index as the only independent variable; potential risk factors were then included in model 2. The variables with significance of < 0.2 in the univariate analyses and which are considered relevant in clinical practice were incorporated in the multivariate regression analyses. Additionally, the multicollinearity test was carried out between the included variables, and those with variance inflation factor > 10 were excluded. The results of the regression analysis were presented with estimated odds ratios (ORs) and 95% confidence intervals (CIs). A two-sided *P*-value of < 0.05 was considered statistically significant. Statistical analysis was performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and IBM SPSS Statistics, version 23.0 for Windows.

Results

Characteristics of patients

Of the 2846 patients, 1449 were female (50.9%) and 1397 were male (49.1%), with an average age of 51.8 ± 3.7 and 41.1 ± 4.2 years, respectively. There were 1093 cases of premature CHD in women (75.4%), and 1068 cases in men (76.4%). Patient characteristics are listed by gender in Additional file 1 (Table A1). The female group had fewer patients with MVD (52.6% vs. 61.2%), smoking (19.4% vs. 73.9%), dyslipidaemia

(64.4% vs. 84.8%), ≥ 3 traditional risk factors (25.7% vs. 46.1%), and old myocardial infarction (3.9% vs. 11.0%) compared with the male group, while more patients had hypertension (65.3% vs. 55.9%) and diabetes (30.0% vs. 22.1%). It was also apparent that the females showed significantly lower levels of TyG Index (8.89 vs. 9.06), TG (1.56 vs. 1.95), CRP (1.51 vs. 2.46), and Cre (56.0 vs. 77.0), and a higher level of LVEF (62.0 vs. 59.0) than the males.

Determinants of premature CHD and TyG index

Among our enrolled patients, men were younger for both premature and mature CHD compared with women. The average age of premature CHD in female and male patients were 50.7 ± 3.6 and 39.7 ± 4.0 , respectively. In the univariate analysis, the clinical characteristics of male patients in the premature and mature CHD groups were similar except for age and FBG, and there was no statistical difference. Significantly higher FBG was shown in the mature group compared to the premature group (5.54 vs. 5.34). For female patients, the proportion of patients diagnosed with hypertension or diabetes in the mature group was higher than that in the premature CHD group (Hypertension: 71.3% vs. 63.3%; Diabetes: 34.3% vs. 28.5%). Also, there were higher level of Lp(a), CRP and Cre in mature patients than in premature patients (Lp(a): 33.0 vs. 25.3; CRP: 1.97 vs. 1.43; Cre: 57.0 vs. 56.0) (Table 1).

Table 1
Baseline characteristics of premature and mature CHD by gender

Variables	Female		<i>P</i> value	Male		<i>P</i> value
	Premature	Mature		Premature	Mature	
	(n = 1093)	(n = 356)		(n = 1068)	(n = 329)	
Age, years	50.7 ± 3.6	55.3 ± 0.5	< 0.001	39.7 ± 4.0	45.3 ± 0.5	< 0.001
BMI, kg/m ²	25.9 ± 2.6	25.7 ± 2.6	0.410	25.8 ± 2.7	26.0 ± 2.6	0.432
Obesity, n (%)	841 (76.9)	269 (75.6)	0.593	811 (75.9)	256 (77.8)	0.484
Smoking, n (%)	212 (19.4)	69 (19.4)	0.995	803 (75.2)	230 (69.9)	0.057
Hypertension, n (%)	692 (63.3)	254 (71.3)	0.006	584 (54.7)	197 (59.9)	0.097
Diabetes, n (%)	312 (28.5)	122 (34.3)	0.041	232 (21.7)	77 (23.4)	0.521
Dyslipidaemia, n (%)	687 (65.5)	206 (61.1)	0.146	862 (85.0)	263 (84.0)	0.672
Family history of CHD, n (%)	220 (20.1)	73 (20.5)	0.878	210 (19.7)	69 (21.0)	0.603
≥ 3 traditional risk factors, n (%)	262 (25.0)	94 (27.9)	0.286	472 (46.5)	140 (44.7)	0.572
Diagnosis, n (%)			0.515			0.746
SA	110 (10.1)	37 (10.4)		97 (9.1)	26 (7.9)	
UA	819 (74.9)	277 (77.8)		538 (50.4)	173 (52.6)	
NSTEMI	45 (4.1)	11 (3.1)		103 (9.6)	35 (10.6)	
STEMI	119 (10.9)	31 (8.7)		330 (30.9)	95 (28.9)	
ACS, n (%)	983 (89.9)	319 (89.6)	0.858	971 (90.9)	303 (92.1)	0.509
OMI, n (%)	41 (3.8)	16 (4.5)	0.531	121 (11.3)	32 (9.7)	0.416
MVD, n (%)	530 (52.5)	176 (52.9)	0.905	617 (60.7)	193 (62.9)	0.500
TyG Index	8.88 (8.49, 9.30)	8.90 (8.49, 9.31)	0.663	9.05 (8.64, 9.45)	9.11 (8.73, 9.54)	0.060
	8.95 ± 0.69	8.96 ± 0.67		9.12 ± 0.70	9.19 ± 0.71	

* MVD: multivessel disease, BMI: body mass index, SA: stable angina, UA: unstable angina, NSTEMI: non-ST-segment elevation myocardial infarction, STEMI: ST-segment elevation myocardial infarction, ACS: acute coronary syndrome, OMI: old myocardial infarction, LVEF: left ventricle ejection fraction, Hb: haemoglobin, FBG: fasting blood glucose, TC: total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, TG: triglyceride, Lp(a): lipoprotein (a), CRP: C-reactive protein, Cre: creatinine.

LVEF, %	62.0 (58.0, 65.0)	62.0 (58.0, 65.0)	0.341	58.0 (52.0, 62.0)	59.0 (54.0, 63.0)	0.187
	61.1 ± 6.7	60.8 ± 6.8		56.5 ± 8.8	57.2 ± 8.1	
Hb, g/L	129.0 (121.0, 137.0)	129.0 (121.0, 137.0)	0.444	150.0 (142.0, 158.0)	149.0 (141.0, 156.0)	0.121
	128.1 ± 13.2	129.0 ± 11.0		149.8 ± 12.5	148.3 ± 14.2	
FBG, mmol/L	5.40 (4.90, 6.79)	5.47 (4.89, 7.03)	0.666	5.34 (4.74, 6.41)	5.54 (4.86, 7.07)	0.003
	6.43 ± 2.64	6.47 ± 2.62		6.12 ± 2.52	6.47 ± 2.52	
TC, mmol/L	4.70 (3.98, 5.39)	4.71 (3.97, 5.57)	0.434	4.63 (3.90, 5.37)	4.52 (3.78, 5.56)	0.815
	4.77 ± 1.13	4.85 ± 1.18		4.72 ± 1.20	4.75 ± 1.30	
LDL-C, mmol/L	3.07 (2.40, 3.73)	3.09 (2.41, 3.83)	0.365	3.05 (2.39, 3.74)	3.01 (2.30, 3.81)	0.709
	3.12 ± 1.00	3.18 ± 1.03		3.13 ± 1.06	3.13 ± 1.14	
HDL-C, mmol/L	1.14 (0.97, 1.35)	1.13 (0.98, 1.33)	0.788	0.90 (0.77, 1.05)	0.93 (0.80, 1.07)	0.105
	1.17 ± 0.29	1.17 ± 0.30		0.93 ± 0.22	0.95 ± 0.23	
TG, mmol/L	1.57 (1.12, 2.18)	1.56 (1.12, 2.24)	0.865	1.93 (1.35, 2.69)	1.96 (1.41, 2.61)	0.691
	1.86 ± 1.31	1.83 ± 1.10		2.37 ± 1.94	2.46 ± 2.38	
Lp(a), mg/L	25.3 (10.0, 68.4)	33.0 (10.7, 93.1)	0.043	18.6 (7.1, 55.0)	19.8 (7.1, 62.2)	0.551
	57.0 ± 75.5	71.1 ± 91.3		43.1 ± 59.6	45.5 ± 59.0	
CRP, mg/L	1.43 (0.61, 3.79)	1.97 (0.74, 4.18)	0.041	2.59 (0.97, 6.58)	2.05 (0.83, 5.31)	0.054
	5.05 ± 19.05	5.39 ± 15.04		9.45 ± 24.70	8.36 ± 22.62	
Cre, µmol/L	56.0 (50.0, 62.8)	57.0 (50.0, 65.0)	0.011	77.0 (69.0, 85.0)	77.0 (69.0, 87.0)	0.451
	57.0 ± 12.4	58.7 ± 12.3		78.4 ± 16.1	79.3 ± 16.1	
<p>* MVD: multivessel disease, BMI: body mass index, SA: stable angina, UA: unstable angina, NSTEMI: non-ST-segment elevation myocardial infarction, STEMI: ST-segment elevation myocardial infarction, ACS: acute coronary syndrome, OMI: old myocardial infarction, LVEF: left ventricle ejection fraction, Hb: haemoglobin, FBG: fasting blood glucose, TC: total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, TG: triglyceride, Lp(a): lipoprotein (a), CRP: C-reactive protein, Cre: creatinine.</p>						

Considerable differences were evident in hypertension, dyslipidaemia, Lp(a) and Cre between premature and mature CHD female patients in the multivariate regression models. Female patients with hypertension were more likely to develop mature CHD than those without hypertension (premature CHD: OR = 0.665, 95%CI:0.505–0.877). The Lp(a) (premature CHD: OR = 0.998, 95%CI:0.996–0.999) and Cre (premature CHD: OR = 0.989, 95%CI:0.979–0.998) levels in the female mature CHD group were higher than those in the premature CHD group. Compared with female patients without dyslipidaemia, those with dyslipidaemia (OR = 1.412, 95%CI:1.029–1.936) were significantly more likely to have premature CHD. Among males with mature CHD, there were a greater number of patients in quartile 4 of TyG index than in quartile 1 (premature CHD: OR = 0.536, 95%CI: 0.338–0.850) (Table 2).

Table 2
Multivariate analysis on the characteristics and determinants of premature CHD compared with mature CHD

Variables	Model1		Model2	
	OR(95%CI)	P value	OR(95%CI)	P value
<i>Female</i>				
TyG Index		0.835		0.793
Quartile 1	1		1	
Quartile 2	0.984(0.705, 1.373)	0.786	0.939(0.659,1.337)	0.681
Quartile 3	0.982(0.697, 1.383)	0.806	0.864(0.576,1.296)	0.763
Quartile 4	0.862(0.612, 1.215)	0.361	0.793(0.500,1.258)	0.382
Obesity			1.051(0.781,1.415)	0.742
Smoking			0.968(0.705,1.329)	0.841
Hypertension			0.665(0.505,0.877)	0.004
Diabetes			0.843(0.620,1.145)	0.274
Dyslipidaemia			1.412(1.029,1.936)	0.033
Family history of CHD			0.947(0.694,1.293)	0.733
Lp(a)			0.998(0.996,0.999)	0.005
CRP			1.001(0.994,1.007)	0.877
Cre			0.989(0.979,0.998)	0.021
<i>Male</i>				
TyG Index		0.141		0.065
Quartile 1	1		1	
Quartile 2	0.755(0.503,1.132)	0.924	0.708(0.463,1.083)	0.868
Quartile 3	0.709(0.478,1.053)	0.502	0.613(0.392,0.958)	0.282
Quartile 4	0.634(0.430,0.934)	0.079	0.536(0.338,0.850)	0.033
Obesity			0.907(0.663,1.241)	0.541
Smoking			1.317(0.987,1.757)	0.061
Hypertension			0.874(0.670,1.140)	0.321
Diabetes			1.028(0.742,1.425)	0.867
* Lp(a): lipoprotein (a), CRP: C-reactive protein, Cre: creatinine.				

Variables	Model1		Model2	
	OR(95%CI)	<i>P</i> value	OR(95%CI)	<i>P</i> value
Dyslipidaemia			1.491(0.990,2.244)	0.056
Family history of CHD			0.923(0.665,1.281)	0.632
Lp(a)			0.999(0.997,1.001)	0.418
CRP			1.003(0.997,1.008)	0.398
Cre			0.997(0.989,1.005)	0.485
* Lp(a): lipoprotein (a), CRP: C-reactive protein, Cre: creatinine.				

The indicators associated with TyG index are showed in Additional file 1 (Table A2 and Table A3). The TyG index levels were positively associated with diabetes (female: $\beta = 0.606$, $P < 0.001$; male: $\beta = 0.556$, $P < 0.001$), dyslipidaemia (female: $\beta = 0.665$, $P < 0.001$; male: $\beta = 0.703$, $P < 0.001$), and Hb (female: $\beta = 0.005$, $P < 0.001$; male: $\beta = 0.004$, $P = 0.007$), and negatively correlated with Lp(a) (female: $\beta = -0.001$, $P < 0.001$; male: $\beta = -0.001$, $P < 0.001$) regardless of gender. Female patients with obesity ($\beta = 0.073$, $P = 0.028$) had a higher TyG index level. Unlike female patients, male patients with a higher CRP level ($\beta = 0.002$, $P = 0.022$) and without OMI ($\beta = -0.119$, $P = 0.033$) or a family history of CHD ($\beta = -0.128$, $P = 0.003$) generally had a higher TyG index.

Factors in the onset age of MVD and SVD

The characteristics of different onset age of MVD and SVD in CHD are presented in Additional file 1 (Table A4 and Table A5). In the crude models, female patients in the highest TyG index level were more likely to have premature MVD (OR = 2.065, 95%CI:1.426–2.991), or mature MVD (OR = 1.837, 95%CI:1.104–3.056) than those in the lowest TyG index group, instead of premature SVD. Among male patients, the same trend was also observed in mature MVD of CHD (OR = 2.272, 95%CI:1.312–3.937) (Table 3). The significance of the TyG index was also not shown in the multivariate analyses. Patients with premature and mature MVD had higher proportion of hypertension, OMI, and higher Lp(a) levels than those with premature SVD. In addition, obesity and lower Hb levels in male patients, and smoking, diabetes, and higher CRP levels in female patients were common risk factors for premature and mature MVD, taking premature SVD as a reference. Nevertheless, the differences in characteristics between the patients with premature SVD and mature SVD were not significant (Fig. 1).

Table 3
Crude models on the risk factors of the onset age of MVD and SVD

Variables	Premature MVD of CHD	<i>P</i> value	Mature SVD of CHD	<i>P</i> value	Mature MVD of CHD	<i>P</i> value
<i>Female</i>	n = 530		n = 157		n = 176	
Model 1						
TyG Index						
Quartile 1	1		1		1	
Quartile 2	0.905(0.643,1.275)	0.570	0.956(0.582,1.572)	0.608	0.966(0.596,1.567)	0.889
Quartile 3	1.273(0.901,1.798)	0.171	1.142(0.688,1.895)	0.859	1.156(0.707,1.892)	0.564
Quartile 4	2.065(1.426,2.991)	< 0.001	1.670(0.982,2.841)	0.058	1.837(1.104,3.056)	0.019
<i>Male</i>	n = 617		n = 114		n = 193	
Model 1						
TyG Index						
Quartile 1	1		1		1	
Quartile 2	1.057(0.720,1.551)	0.778	1.177(0.624,2.222)	0.614	1.492(0.833,2.672)	0.178
Quartile 3	1.104(0.757,1.609)	0.608	1.184(0.633,2.215)	0.597	1.704(0.967,3.003)	0.065
Quartile 4	1.110(0.762,1.619)	0.586	1.107(0.588,2.086)	0.752	2.272(1.312,3.937)	0.003
* SVD: single-vessel disease, MVD: multivessel disease.						

Discussion

We compared the clinical characteristics of premature CHD with mature CHD patients and explored the risk factors for the vascular disease severity on premature and mature CHD. Our results show that female patients in the premature group had a higher rate of dyslipidaemia than those in the mature group. When including the TyG index only, female patients with MVD and male patients with mature MVD were more likely to have higher levels than those with premature SVD. Additionally, significantly higher rates of hypertension, diabetes, OMI, smoking (female), obesity (male), and higher levels of Lp(a) and CRP (female) were observed in patients with MVD, considering traditional risk factors and other clinical indicators.

One important finding was that the differences in most characteristics between premature and mature CHD patients were not statistically significant. Also, among the few statistically significant risk factors, the proportions and levels were higher in mature patients than in premature patients. Only dyslipidaemia was found the opposite trend for female patients. Several previous studies have explored the association between risk factors and onset age of CHD. Our finding is similar to that of Mohammad et al. who found that premature CHD patients had higher rates of hyperlipidaemia and family history of CHD than mature patients [14]. However, this is inconsistent with the results of Zhou et al., who found that the rates of family history of hypertension, diabetes and the levels of BMI, TG, TC and LDL-C in the premature CHD group were higher than those in the mature group [6]. Both studies found more patients with MVD among the mature CHD group than the premature group, which was not observed in our study [6, 14]. One explanation for the divergence in the results is that the studies enrolled different populations and sample sizes. In addition, our study added stratified analyses by gender and included new risk factors for CHD, such as TyG index, Lp(a), CRP, and Cre for multivariate analysis. All of the above may contribute to the discrepancies seen with the previous study.

The higher rate of hypertension and higher levels of Lp(a), Cre, and TyG index in mature CHD may be explained by the fact that the prevalence of hypertension as well as the level of Lp(a), Cre, and TyG index rose with elevated age [4, 29–31]. The onset of CHD in women comes later than in men by 7–10 years because of the role of endogenous estrogen in enhancing vascular relaxation and improving blood lipids and blood coagulation [32, 33]. However, CHD mortality is higher in women than in men because of this late onset [34]. This study observed a higher incidence of dyslipidaemia in premature CHD female patients, which is consistent with the findings of Penida et al [35]. This reveals that general practitioners and clinicians should pay more attention to the early prevention of dyslipidaemia in women at a young age, and patients with dyslipidaemia should regularly participate in cardiovascular disease screening.

IR is defined as a sensitivity reduction in insulin-dependent cells' response to insulin [36]. It induces an imbalance in glucose metabolism and leads to dyslipidaemia and lipid triad, which each contribute to CVD and atherosclerotic plaque generation [37]. The TyG index proposed by Simental-Mendia et al. could be useful as a simple and reliable surrogate to measure IR in clinical practice [28]. Compared with traditional indices for predicting IR, HOMA-IR, the TyG index is easier to obtain and has higher sensitivity [18, 21, 28]. Also, Kim et al., Park et al., and Su et al. identified that an increased TyG index is associated with a raised risk of CHD [18, 20, 38]. In our study, no difference was found on the TyG index between the premature and mature CHD groups in univariate analyses, while the multivariate analyses showed that more male patients with premature CHD had a lower level of TyG index. The TyG index thus did not present superiority in predicting premature CHD. Furthermore, the TyG index was positively associated with diabetes, dyslipidaemia, Hb, obesity, and CRP, which is partly consistent with the results of Jin et al. and Wang et al. [17, 19, 21]. The main explanation for this correlation is that most of these factors are components of metabolic syndrome and IR [19].

In this study, the TyG Index was used as one of the markers of CHD vascular disease severity, which was reflected by whether the patients had SVD or MVD. Although it is not claimed that MVD of CHD is more severe than SVD, a published study identified that patients with MVD are more likely to experience

complications with diabetes, renal insufficiency, and history of myocardial infarction compared with those with SVD [39]. Also, Part et al. and Lopes et al. found that MVD was associated with a worse prognosis than SVD [22, 40]. Therefore, prevention of MVD risk factors and early prediction of the number of diseased vessels could reduce the risk and burden of CHD through appropriate interventions [2]. Our finding that patients with MVD of both premature and mature CHD generally had more patients with the highest TyG index than those with premature SVD is consistent with that of Mao et al. [19]. The correlation between TyG index and vascular disease severity disappeared after adjusting for traditional CHD risk factors; however, other risk factors such as hypertension, diabetes, obesity, smoking, OMI, and Lp(a) showed a positive association with vascular disease severity. This may be because TyG index is associated with cardiometabolic risk factors, which have a stronger effect on the vascular disease severity than TyG index in the models [19]. This suggests that TyG index should be added as one of the risk factors for CHD or CVD screening, and could be used as an auxiliary indicator for identifying vascular disease severity.

Strengths And Limitations

To our knowledge, this study is the first to fully explore the correlation between the risk factors and the onset age of CHD and vascular disease severity, and also to include TyG index as a potential risk factor. Compared with previously published studies, this study has a larger sample size, and all the patients enrolled were of a younger age, which aptly reflects the real clinical characteristics of patients with premature CHD. However, this study has several limitations. First, the distribution of characteristics between patients in the premature and mature groups was similar due to the young age of the entire study population. Second, this study only collected the baseline data of patients at the time of attendance and did not conduct follow-up; therefore, the correlation between onset age and risk factors of CHD and disease progression and prognosis cannot be explored. Third, OGTT was requested only in patients with diabetic symptoms, which may lead to missed diagnosis some diabetics. Fourth, the family history of CHD relied on self-reports from patients, which tends to lead to information bias.

Conclusions

The similarity of most characteristics in our study between the premature and mature CHD groups suggests that these risk factors cannot be used to determine whether or not patients would experience CHD in early age. We identify that dyslipidaemia should be used as an effective indicator for the prediction and prevention of premature CHD in women in public health strategies. The TyG index may prove to be a simple and accessible auxiliary indicator to be applied in population-based cardiovascular disease screening for initial identification of vascular disease severity. Finally, an aggressive management and prevention strategy for diabetes, hypertension, obesity, OMI, and Lp(a), along with smoking cessation, are effective measures to reduce MVD of CHD. Further studies could quantify the cut-off value of TyG index in predicting premature CHD and MVD.

Abbreviations

CVD

Cardiovascular disease
CHD
Coronary heart disease
ACS
Acute coronary syndrome
IR
insulin resistance
TyG index
Triglyceride-glucose index
MVD
Multivessel disease
SVD
Single-vessel disease
SA
Stable angina
UA
Unstable angina
NSTEMI
Non-ST-segment elevation myocardial infarction
STEMI
ST-segment elevation myocardial
infarction
PCI
Percutaneous coronary intervention
CABG
Coronary artery bypass grafting
BMI
Body mass index
LVEF
Left ventricle ejection fraction
Hb
Haemoglobin
FBG
Fasting blood glucose
TC
Total cholesterol
LDL-C
Low-density lipoprotein cholesterol
HDL-C
High-density lipoprotein cholesterol
TG

Triglyceride
Lp(a)
Lipoprotein (a)
CRP
C-reactive protein
Cre
Creatinine
OMI
Old myocardial infarction
OGTT
Oral glucose tolerance test
IQR
Inter-quartile range
OR
Odds ratio
CI
Confidence interval.

Declarations

Ethics approval and consent to participate: This study adhered to the Declaration of Helsinki and was approved by the Medical Ethics Committee of Tianjin Chest Hospital (No. 2018XKZ23). All patients enrolled in this study provided verbal informed consent.

Consent for publication: Not applicable.

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: This study was supported by Tianjin Chest Hospital (No. 2018XKZ23) and Tianjin Municipal Health Commission (No. KJ20088). The funder had no role in the study design, data collection and analysis, interpretation, or reporting of the results.

Authors' contributions: HC and AW contributed to conception and design of the study. AW, JL, and LW collected, cleaned, and coded the study data. HC supervised the research process. AW and LW performed the statistical analysis. AW and JL wrote the first draft of the manuscript. LW and SZ wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the final version. All authors agreed to the published the manuscript.

Acknowledgements: We acknowledge all patients participating in the project.

References

1. World Health Organization. Cardiovascular diseases (CVDs). [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)). Accessed 20 January 2022.
2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010.
3. National Center for Cardiovascular Diseases. Annual Report on Cardiovascular Health and Diseases in China (2019). China: Science Press; 2020.
4. Ge JB, Xu YJ, Wang C. Internal Medicine. 9th ed. China: People's Medical Publishing House; 2018.
5. Institute for Health Metrics and Evaluation. Global Burden of Disease: University of Washington. 2019. <https://vizhub.healthdata.org/gbd-compare/>. Accessed 20 January 2022.
6. Zhou X, Shi SP, Zeng LQ. Comparative Study for Risk Factors and Features in Patients With Premature Coronary Artery Disease and Mature Coronary Artery Disease. *Chinese Circulation Journal*. 2017;32(7):638–41. doi: 10.3969/j.issn.1000-3614.2017.07.004.
7. Institute for Health Metrics and Evaluation. Global Burden of Disease Results Tool: University of Washington. 2019. <http://ghdx.healthdata.org/gbd-results-tool>. Accessed 20 January 2022.
8. De Sutter J, De Bacquer D, Kotseva K, Sans S, Pyorala K, Wood D, et al. Screening of family members of patients with premature coronary heart disease; results from the EUROASPIRE II family survey. *Eur Heart J*. 2003;24(3):249–57. doi: 10.1016/S0195-668X(02)00386-X.
9. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Journal of the American College of Cardiology*. 2012;60(24):e44-e164. doi: 10.1016/j.jacc.2012.07.013.
10. Liu ZY, Li G, Li YD, Yang QQ, Han XH. Clinical study on the risk factors and coronary features of patients with premature coronary heart disease. *Chinese Journal of Cardiovascular Research*. 2008;6(9):657–9. doi: 10.3969/j.issn.1672-5301.2008.09.007.
11. Zeitouni M, Clare RM, Chiswell K, Abdulrahim J, Shah N, Pagidipati NP, et al. Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease. *J Am Heart Assoc*. 2020;9(24):e017712. doi: 10.1161/JAHA.120.017712.
12. Gupta R, Wood DA. Primary prevention of ischaemic heart disease: populations, individuals, and health professionals. *Lancet*. 2019;394(10199):685–96. doi: 10.1016/S0140-6736(19)31893-8.
13. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. *J Cell Physiol*. 2019;234(10):16812–23. doi: 10.1002/jcp.28350.
14. Mohammad AM, Jehangeer HI, Shaikhow SK. Prevalence and risk factors of premature coronary artery disease in patients undergoing coronary angiography in Kurdistan, Iraq. *BMC Cardiovasc Disord*.

- 2015;15:155. doi: 10.1186/s12872-015-0145-7.
15. Panwar RB, Gupta R, Gupta BK, Raja S, Vaishnav J, Khatri M, et al. Atherothrombotic risk factors & premature coronary heart disease in India: a case-control study. *Indian J Med Res.* 2011;134:26–32.
 16. Singh A, Gupta A, Collins BL, Qamar A, Monda KL, Biery D, et al. Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. *Journal of the American College of Cardiology.* 2019;73(19):2439–50. doi: 10.1016/j.jacc.2019.02.059.
 17. Jin JL, Cao YX, Wu LG, You XD, Guo YL, Wu NQ, et al. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. *J Thorac Dis.* 2018;10(11):6137–46. doi: 10.21037/jtd.2018.10.79.
 18. Kim MK, Ahn CW, Kang S, Nam JS, Kim KR, Park JS. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. *Cardiovasc Diabetol.* 2017;16(1):108. doi: 10.1186/s12933-017-0589-4.
 19. Mao Q, Zhou D, Li Y, Wang Y, Xu SC, Zhao XH. The Triglyceride-Glucose Index Predicts Coronary Artery Disease Severity and Cardiovascular Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. *Dis Markers.* 2019;2019:6891537. doi: 10.1155/2019/6891537.
 20. Park GM, Cho YR, Won KB, Yang YJ, Park S, Ann SH, et al. Triglyceride glucose index is a useful marker for predicting subclinical coronary artery disease in the absence of traditional risk factors. *Lipids Health Dis.* 2020;19(1):7. doi: 10.1186/s12944-020-1187-0.
 21. Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. *Cardiovasc Diabetol.* 2020;19(1):80. doi: 10.1186/s12933-020-01054-z.
 22. Park DW, Clare RM, Schulte PJ, Pieper KS, Shaw LK, Califf RM, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. *JAMA.* 2014;312(19):2019–27. doi: 10.1001/jama.2014.15095.
 23. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Eur Heart J.* 2007;28(14):1709–16. doi: 10.1093/eurheartj/ehm184.
 24. Yan HB, Ma CS, Huo Y. Clinical guidelines for the diagnosis and treatment of coronary heart disease. 1st ed. China: People's Medical Publishing House; 2010.
 25. National Health Commission of the People's Republic of China. Chinese guidelines for the management of overweight and obesity in Adults. China: People's Medical Publishing House; 2006.
 26. Zhu JR, Gao RL, Zhao SP, Lu GP, Zhao D, Li JJ. 2016 Chinese guideline for the management of dyslipidaemia in adults. *Chinese Circulation Journal.* 2016;31(10):937 – 53. doi: 10.3969/j.issn.1000-3614.2016.10.001.
 27. Vogel B, Mehta SR, Mehran R. Reperfusion strategies in acute myocardial infarction and multivessel disease. *Nat Rev Cardiol.* 2017;14(11):665–78. doi: 10.1038/nrcardio.2017.88.

28. Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. *Metab Syndr Relat Disord*. 2008;6(4):299–304. doi: 10.1089/met.2008.0034.
29. Akita H, Matsubara M, Shibuya H, Fuda H, Chiba H. Effect of ageing on plasma lipoprotein(a) levels. *Ann Clin Biochem*. 2002;39(Pt 3):237–40. doi: 10.1258/0004563021901937.
30. Tiao JY, Semmens JB, Masarei JR, Lawrence-Brown MM. The effect of age on serum creatinine levels in an aging population: relevance to vascular surgery. *Cardiovasc Surg*. 2002;10(5):445–51. doi: 10.1016/S0967-2109(02)00056-X.
31. Chamroonkiadtikun P, Ananchaisarp T, Wanichanon W. The triglyceride-glucose index, a predictor of type 2 diabetes development: A retrospective cohort study. *Prim Care Diabetes*. 2020;14(2):161–7. doi: 10.1016/j.pcd.2019.08.004.
32. Duda-Pyszny D, Trzeciak P, Gasior M. Coronary artery disease in women. *Kardiochir Torakochirurgia Pol*. 2018;15(1):44–8. doi: 10.5114/kitp.2018.74675.
33. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. *Pharmacol Ther*. 2012;135(1):54–70. doi: 10.1016/j.pharmthera.2012.03.007.
34. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. *Circulation*. 2012;125(1):e2–e220. doi: 10.1161/CIR.0b013e31823ac046.
35. Pineda J, Marin F, Roldan V, Valencia J, Marco P, Sogorb F. Premature myocardial infarction: clinical profile and angiographic findings. *Int J Cardiol*. 2008;126(1):127–9. doi: 10.1016/j.ijcard.2007.02.038.
36. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. *J Clin Invest*. 2016;126(1):12–22. doi: 10.1172/JCI77812.
37. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuniga FA. Association between insulin resistance and the development of cardiovascular disease. *Cardiovasc Diabetol*. 2018;17(1):122. doi: 10.1186/s12933-018-0762-4.
38. Su WY, Chen SC, Huang YT, Huang JC, Wu PY, Hsu WH, et al. Comparison of the Effects of Fasting Glucose, Hemoglobin A1c, and Triglyceride-Glucose Index on Cardiovascular Events in Type 2 Diabetes Mellitus. *Nutrients*. 2019;11(11):2838. doi: 10.3390/nu11112838.
39. Zhang XY, Ma CS. Revascularization strategy for patients with multivessel disease. *Adv Cardiovasc Dis*. 2009;30(2):197–200. doi: 10.3969/j.issn.1004-3934.2009.02.004.
40. Lopes NH, Paulitsch Fda S, Gois AF, Pereira AC, Stolf NA, Dallan LO, et al. Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the Medical, Angioplasty, and bypass Surgery study (MASS). *Eur J Cardiothorac Surg*. 2008;33(3):349–54. doi: 10.1016/j.ejcts.2007.11.025.

Figures

Figure 1

Multivariate analysis on the risk factors of the onset age of MVD and SVD in CHD compared with premature SVD of CHD. (a) Premature MVD of CHD; (b) Mature SVD of CHD; (c) Mature MVD of CHD

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.docx](#)